Periodontal repair in dogs: evaluation of rhBMP-2 carriers.
This study evaluated candidate carriers for recombinant human bone morphogenetic protein-2 (rhBMP-2)-driven periodontal regeneration. Previous experiments indicated the ability of rhBMP-2 in a particulate delivery system to result in substantial regeneration of bone and periodontal regeneration. In the present study, canine demineralized bone matrix (DBM), bovine deorganified crystalline bone matrix (Bio-Oss), an absorbable collagen sponge (ACS) of type I bovine collagen, poly(D,L-lactide-co-glycolide) microparticles (PLGA), and polylactic acid granules (Drilac) were tested for their ability to support rhBMP-2 (0.2 mg/mL implant volume)-driven periodontal regeneration. The implants were tested in routine critical size canine supra-alveolar periodontal defects with transgingival tooth positioning. Contralateral defects in six beagle dogs were semirandomly assigned to receive: DBM/rhBMP-2, DBM (no rhBMP-2), Bio-Oss/rhBMP-2, ACS/rhBMP-2, PLGA/rhBMP-2, or Drilac/rhBMP-2. Animals were sacrificed 8 weeks postsurgery, and block sections of the defects were processed for light microscopy. Substantial bone regeneration was observed in all defects implanted with rhBMP-2. Other measures of periodontal healing, including cementum regeneration and presence of ankylosis, were more variable between the implants. DBM and Bio-Oss performed well as carriers for rhBMP-2-driven periodontal regeneration, although other impediments to their clinical use exist. This study indicates that qualities of the carrier system, including its space-maintaining capacity can affect the ability of rhBMP-2 to regenerate both alveolar bone and periodontal attachment.
Sigurdsson
T J
TJ
Loma Linda University, California 92354, USA.
Nygaard
L
L
Tatakis
D N
DN
Fu
E
E
Turek
T J
TJ
Jin
L
L
Wozney
J M
JM
Wikesjö
U M
UM
D016301:Alveolar Bone Loss / Q000601:surgery / Q000628:therapy*; D000818:Animals; D001672:Biocompatible Materials; D001857:Bone Matrix; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D002417:Cattle; D003094:Collagen; D004285:Dogs; D004337:Drug Carriers; D005069:Evaluation Studies as Topic; D006801:Humans; D019344:Lactic Acid; D008297:Male; D008903:Minerals; D011091:Polyesters; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D019736:Prostheses and Implants; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012391:Root Resorption; D013524:Surgical Flaps; D014092:Tooth Root / Q000033:anatomy & histology
C077540:Bio-Oss; D001672:Biocompatible Materials; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D008903:Minerals; D011091:Polyesters; D011108:Polymers; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C033616:poly(lactide); D003094:Collagen